Use of the case-control approach in vaccine evaluation: Efficacy and adverse effects

Epidemiologic Reviews

Volumn 21, Issue 1, 1999, Pages 56-72

  Rodrigues, L C ^a   Smith, R G ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; INFECTION PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION;

EID: 0032844955     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017988     Document Type: Review

References (119)

1. Sartwell PE. Retrospective studies: a review for the clinician. Ann Intern Med 1974;81:381-6.
2. Weiss ES, Kendrick PL. The effectiveness of pertussis vaccine: an application of Sargent and Merrell's method of measurement. Am J Hyg 1943;38:306-9.
3. Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention: first report. Bull World Health Organ 1979;57:819-27.
4. World Health Organization. BCG vaccination policies. Geneva, Switzerland: World Health Organization, 1980.
5. Smith PG. Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method. Tubercle 1982;63:23-35.
6. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984;6:589-600.
7. Fleiss JL. Statistical methods for rates and proportions. New York, NY: John Wiley and Sons, Inc, 1973.
8. Smith PG, Rodrigues LC, Fine PE. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984; 13: 87-93.
9. Rodrigues L, Kirkwood BR. Case-control design in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol 1990;19:205-13.
10. de Moraes JC, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
11. Miller DL, Ross EM, Alderslade R, et al. Pertussis immunisation and serious acute neurological illness in children. Br Med J (Clin Res Ed) 1981;282:1595-9.
12. Bowie C. Lessons from the pertussis vaccine court trial. Lancet 1990;335:397-9.
13. Judgement no. 1982 L 1812. Susan Loveday suing Dr. G. H. Renton and The Wellcome Foundation Limited. Before the Right Honourable Lord Justice Stuart-Smith. London, England: The High Court of Justice, Queen's Bench Division, 1988:76.
14. Wentz KR, Marcuse EK. Diphtheria-tetanus-pertussis vaccine and serious neurologic illness: an updated review of the epidemiologic evidence. Pediatrics 1991;87:287-97.
15. Marcuse EK, Wentz KR. The NCES reconsidered: summary of a 1989 workshop. National Childhood Encephalopathy Study. Vaccine 1990;8:531-5.
16. American Academy of Pediatrics, Committee on Infectious Diseases. The relationship between pertussis vaccine and brain damage: reassessment. Pediatrics 1991;88:397-400.
17. Begg N, Miller E. Role of epidemiology in vaccine policy. Vaccine 1990;8:180-9.
18. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
19. Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988;44:691-703.
20. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154-8.
21. Comstock GW. Vaccine evaluation by case-control or prospective studies. Am J Epidemiol 1990;131:205-7.
22. Strassburg MA, Greenland S, Stephenson TG, et al. Clinical effectiveness of rubella vaccine in a college population. Vaccine 1985;3:109-12.
23. Davis RM, Whitman ED, Orenstein WA, et al. A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol 1987;126:438-49.
24. Wassilak SG, Orenstein WA, Strickland PL, et al. Continuing measles transmission in students despite school-based outbreak control program. Am J Epidemiol 1985;122:208-17.
25. Harrison LH, Tajkowski C, Croll J, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994;125:571-6.
26. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984;101:325-30.
27. Rodrigues LC, Noel Gill O, Smith PG. BCG vaccination in the first year of life protects children of Indian subcontinent ethnic origin against tuberculosis in England. J Epidemiol Community Health 1991;45:78-80.
28. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes: a case-control study. Am J Epidemiol 1986;124:114-19.
29. Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995;346:591-5.
30. Muliyil J, Nelson KE, Diamond EL. Effect of BCG on the risk of leprosy in an endemic area: a case control study. Int J Lepr Other Mycobact Dis 1991;59:229-36.
31. Clemens JD, Stanton BF, Chakraborty J, et al. Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988;128:1330-9.
32. Aaby P, Samb B, Simondon F, et al. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ 1995;311:481-5.
33. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992;136:296-307.
34. Clemens JD, Sack DA, Harris JR, et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 1990;131:400-11.
35. Halsey NA, Modlin JF, Jabbour JT, et al. Risk factors in sub-acute sclerosing panencephalitis: a case-control study. Am J Epidemiol 1980;111:415-24.
36. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
37. Joseph KS, Joseph A. A potential bias in the estimation of vaccine efficacy through observational study designs. (Letter). Int J Epidemiol 1989;18:729-31.
38. Greenland S, Frerichs RR. On measures and models for the effectiveness of vaccines and vaccination programmes. Int J Epidemiol 1988;17:456-63.
39. Haber M, Orenstein WA, Halloran ME, et al. The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak. Am J Epidemiol 1995;141:980-90.
40. Wunsch-Filho V, Moncau JE, Nakao N. Methodological considerations in case-control studies to evaluate BCG vaccine effectiveness. Int J Epidemiol 1993;22:149-55.
41. Clarkson JA, Fine PE. An assessment of methods for routine local monitoring of vaccine efficacy, with particular reference to measles and pertussis. Epidemiol Infect 1987;99: 485-99.
42. Noah N. Transmissible agents. In: Holland WW, Detels R, Knox G, eds. Oxford textbook of public health. 2nd ed. Oxford, England: Oxford University Press, 1991.
43. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985;63: 1055-68.
44. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev 1988;10:212-41.
45. Fine PE. Implications of different study designs for the evaluation of acellular pertussis vaccines. Dev Biol Stand 1997;89:123-33.
46. Fine PE, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 1987;9:866-83.
47. Comstock G. Prevention of tuberculosis. Bull Int Union Tuberc Lung Dis 1990;91:9-11.
48. Miceli I, de Kantor IN, Colaiacovo D, et al. Evaluation of the effectiveness of BCG vaccination using the case-control method in Buenos Aires, Argentina. Int J Epidemiol 1988;17:629-34.
49. Haber M, Longini IM Jr, Halloran ME. Estimation of vaccine efficacy in outbreaks of acute infectious diseases. Stat Med 1991;10:1573-84.
50. Longini IM Jr, Halloran ME, Haber M. Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity. Math Biosci 1993;117: 271-81.
51. Farrington CP. The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 1992;21:1014-20.
52. Halloran ME, Longini IM Jr, Struchiner CJ. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 1996;144:83-97.
53. Halloran ME, Haber M, Longini IM Jr. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992;136:328-43.
54. Halloran ME, Watelet L, Struchiner CJ. Epidemiologic effects of vaccines with complex direct effects in an age-structured population. Math Biosci 1994;121:193-225.
55. Brunet RC, Struchiner CJ, Halloran ME. On the distribution of vaccine protection under heterogeneous response. Math Biosci 1993;116:111-25.
56. Wharton M, Cochi SL, Hutcheson RH, et al. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988;158: 1253-60.
57. Longini IM Jr, Halloran ME, Haber M, et al. Measuring vaccine efficacy from epidemics of acute infectious agents. Stat Med 1993;12:249-63.
58. Haber M, Watelet L, Halloran ME. On individual and population effectiveness of vaccination. Int J Epidemiol 1995;24:1249-60.
59. Haber M, Longini IM Jr, Halloran M. Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol 1991;20:300-10.
60. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
61. Sutherland I, Springett VH. Effectiveness of BCG vaccination in England and Wales in 1983. Tubercle 1987;68:81-92.
62. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993;22:742-6.
63. Moulton LH, Wolff MC, Brenneman G, et al. Case-cohort analysis of case-coverage studies of vaccine effectiveness. Am. J Epidemiol 1995;142:1000-6.
64. Sims RV, Steinmann WC, McConville JH, et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
65. Gebo KA. Moore RD, Keruly JC, et al. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996;173:857-62.
66. Malfait P, Jataou IM, Jollet MC, et al. Measles epidemic in the urban community of Niamey: transmission patterns, vaccine efficacy and immunization strategies, Niger, 1990 to 1991. Pediatr Infect Dis J 1994;13:38-45.
67. Pinner RW, Onyango F, Perkins BA, et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis 1992;166:359-64.
68. Struchiner CJ, Halloran ME, Robins JM, et al. The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns - a computer simulation study of malaria vaccines. Int J Epidemiol 1990;19:187-96.
69. Struchiner CJ, Halloran ME, Spielman A. Modeling malaria vaccines. I. New uses for old ideas. Math Biosci 1989; 94:87-113.
70. Killewo J, Makwaya C, Munubhi E, et al. The protective effect of measles vaccine under routine vaccination conditions in Dar es Salaam, Tanzania: a case-control study. Int J Epidemiol 1991;20:508-14.
71. McDonnell LF, Jorm LR, Patel MS. Measles outbreak in western Sydney: vaccine failure or failure to vaccinate? Med J Aust 1995;162:471-5.
72. Fine PE, Ponnighaus JM, Maine N. The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 1989;67:35-42.
73. Deivanayagam N, Nedunchelian K, Ahamed SS, et al. Clinical efficacy of trivalent oral poliomyelitis vaccine: a case-control study. Bull World Health Organ 1993;71:307-9.
74. Balraj V, John TJ, Thomas M, et al. Efficacy of oral poliovirus vaccine in rural communities of North Arcot District, India. Int J Epidemiol 1990;19:711-14.
75. Robertson SE, Traverse HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;1:897-9.
76. Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996;347:1583-6.
77. Deming MS, Linkins RW, Jaiteh KO, et al. The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. J Infect Dis 1997;175(suppl 1):S254-7.
78. Bentsi Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15: 301-6.
79. Kotb MM, Shouman AE, Mortagy A. Epidemiological evaluation of oral polio vaccine efficacy in Cairo. J Egypt Public Health Assoc 1993;68:617-25.
80. De Serres G, Boulianne N, Meyer F, et al. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect 1995;115:315-23.
81. Rivest P, Bedard L, Arruda H, et al. Risk factors for measles and vaccine efficacy during an epidemic in Montreal. Can J Public Health 1995;86:86-90.
82. Simba DO, Msamanga GI. Measles vaccine effectiveness under field conditions: a case control study in Tabora region, Tanzania. Trop Geogr Med 1995;47:197-9.
83. Hull HF, Montes JM, Hays PC. Risk factors for measles vaccine failure among immunized students. Pediatrics 1985;76:518-23.
84. Vadheim CM, Greenberg DP, Bordenave N, et al. Risk factors for invasive Haemophilus influenzae type b in Los Angeles County children 18-60 months of age. Am J Epidemiol 1992;136:221-35.
85. Yuan L. Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. CMAJ [Can Med Assoc J] 1994;150:1093-8.
86. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200-7.
87. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine Lancet 1985;2:114-18.
88. Ahmed AH, Nicholson KG, Nguyen-van Tam JS, et al Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic. Epidemiol Infect 1997;118:27-33.
89. Greenberg DP, Vadheim CM, Bordenave N, et al. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older. JAMA 1991;265:987-92.
90. Victora CG, Fuchs SC, Kirkwood BR, et al. Breast-feeding, nutritional status, and other prognostic factors for dehydration among young children with diarrhoea in Brazil. Bull World Health Organ 1992;70:467-75.
91. Orege PA, Fine PE, Lucas SB, et al. Case-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya. Int J Lepr Other Mycobact Dis 1993;61: 542-9.
92. Lyons RA, Jones HI, Salmon RL. Successful control of a school based measles outbreak by immunization. Epidemiol Infect 1994;113:367-75.
93. Connolly AM, Salmon RL, Lervy B, et al. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in general practice. BMJ 1993;306:1452-4.
94. Black SB, Shinefield HR, Hiatt RA, et al. Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine. Pediatr Infect Dis J 1988;7:149-56.
95. Rajapaksa L. A case control study to assess the efficacy of measles vaccine. Ceylon Med J 1993;38:178-80.
96. Vadheim CM, Greenberg DP, Eriksen E, et al. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study. Pediatr Infect Dis J 1994;13:274-80.
97. Wunsch Filho V, de Castilho EA, Rodrigues LC, et al. Effectiveness of BCG vaccination against tuberculous meningitis: a case-control study in Sao Paulo, Brazil. Bull World Health Organ 1990;68:69-74.
98. Ramasamy DJ. Field evaluation of trivalent oral polio vaccine efficacy in Madras city - a case control study. J Commun Dis 1994;26:151-5.
99. Salisbury DM, Begg NT. Immunization against infectious disease. London, England: HMSO, 1996.
100. Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep 1997;112:10-20.
101. Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Events Reporting System (1990 to 1994). Pediatr Infect Dis J 1996;15:88-90.
102. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/ tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345:567-9.
103. Nash JQ, Chandrakumar M, Farrington CP, et al. Feasibility study for identifying adverse events attributable to vaccination by record linkage. Epidemiol Infect 1995;114:475-80.
104. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoidnodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351: 637-41.
105. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992;136:121-35.
106. Fine PE. Methodological issues in the evaluation and monitoring of vaccine safety. Ann N Y Acad Sci 1995;754:300-8.
107. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143:1165-73.
108. Miller D, Madge N, Diamond J, et al. Pertussis immunisation and serious acute neurological illnesses in children. BMJ 1993;307:1171-6.
109. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 1984;14:1-78.
110. Griffith AH. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine 1989;7:199-210.
111. Sepkowitz S. Perverse reactions to pertussis vaccine by government medical agencies. J Okla State Med Assoc 1996;89: 135-8.
112. Cowan LD, Griffin MR, Howson CP, et al. Acute encephalopathy and chronic neurological damage after pertussis vaccine. Vaccine 1993;11:1371-9.
113. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one-to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J 1997;16:500-3.
114. Chen RT, Classer JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997;99:765-73.
115. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995;51: 228-35.
116. Thompson NP, Fleming DM, Pounder RE, et al. Crohn's disease, measles, and measles vaccination: a case-control failure. (Letter). Lancet 1996;347:263.
117. Thompson NP, Pounder RE, Wakefield AJ. Perinatal and childhood risk factors for inflammatory bowel disease: a case-control study. Eur J Gastroenterol Hepatol 1995;7: 385-90.
118. Feeney M, Ciegg A, Winwood P, et al. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 1997;350:764-6.
119. Halloran ME, Longini IM Jr, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev 1999;21:73-88.